Citations

Clear

14 citation(s) found for "Bobart, Shane A".

Serologic Discrimination of Histologic Classes in Lupus Nephritis
Fatfat, Adnan , Batish, Ishaan, Sharma, Abhinav , Arevalo Salazar, Dory , Albadri, Sam , Majithia, Vikas , Aslam, Nabeel , Bobart, Shane A

Mayo Clinic

Kidney360 | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34067/kid.0000001453 | PMID 43023780 Get It

Background: Anti-dsDNA positivity and hypocomplementemia are markers of active lupus nephritis (LN), but their ability to discriminate between histologic phenotypes remains underexplored, particularly for mixed proliferative/membranous LN (mixed LN). We compared baseline serologic markers across proliferative LN, membranous LN, and mixed LN, and evaluated their discriminative performance for histologic class. Methods: We conducted a retrospective cross-sectional study of 132 patients with biopsy-proven LN, categorized according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification into proliferative LN (class III/IV), membranous LN (class V), and mixed LN (class III/IV+V). Baseline anti-dsDNA and complements C3 and C4 were compared across groups. Receiver operating characteristic (ROC) analysis assessed the ability of individual and combined markers to discriminate between histologic classes. Kidney outcomes at 12 months were explored in a secondary cohort (n=88). Results: Of 132 patients, 57 had proliferative LN, 32 had membranous LN, and 43 had mixed LN. Anti-dsDNA was significantly higher, and C3 and C4 significantly lower, in proliferative and mixed LN compared to membranous LN ( P <0.05 for all), while proliferative and mixed LN did not differ significantly. On ROC analysis, individual markers achieved AUCs of 0.68-0.71 for distinguishing proliferative or mixed LN from membranous LN, with combined models yielding AUCs of 0.73. However, discrimination between proliferative and mixed LN was poor (combined AUC 0.62). At 12 months, kidney outcomes were comparable across groups. Conclusions: Mixed LN exhibits a serologic profile resembling proliferative LN, both sharing elevated anti-dsDNA and low complement levels, but distinct from membranous LN. Serology could inform suspicion for LN class but cannot replace kidney biopsy.
Fibrillary Glomerulonephritis: Clinicopathologic Features and Outcomes
Sawaf, Hanny , Osman, Omar, Borghol, Abdul Hamid , Gudura, Tariku T., Herlitz, Leal, Cohen, Scott, Gebreselassie, Surafel , Bobart, Shane A. , Gudura, Tariku Tadele, Mehdi, Ali

Mayo Clinic

No container title available | July 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9665759/v1 Get It

Abstract Background: Fibrillary glomerulonephritis (FGN) is a rare immune-mediated glomerular disease characterized by glomerular fibrillar deposits and historically associated with poor kidney outcomes. Despite recent diagnostic advances, including DNAJB9 immunohistochemistry, the clinical spectrum, prognostic factors, and optimal management of FGN remain incompletely defined. Methods: We conducted a retrospective cohort study of patients with biopsy-proven FGN identified through the Cleveland Clinic Kidney Biopsy Epidemiology Project between January 2015 and March 2023. Results: Thirty patients met inclusion criteria. The cohort was predominantly female (70%) and white (86%), with a median age of 64 years. At the time of kidney biopsy, all patients had hypertension and acute or chronic kidney disease. Additional features included hematuria (76%), proteinuria (60%), and nephrotic syndrome (48%). Monoclonal protein was detected in 20% of cases. During a mean follow-up of 24 months (range 0–70 months; n = 13), 23% achieved partial remission, 23% had persistent disease, and 53% progressed to end-stage kidney disease (ESKD). Higher serum creatinine at biopsy was the only variable associated with progression to ESKD. Conclusion: FGN remains a rare glomerular disease with substantial risk of progression to kidney failure. This single-center cohort highlights the heterogeneous clinical presentation and generally poor kidney outcomes of FGN in the modern diagnostic era. Larger, multicenter studies are needed to refine prognostic stratification and guide evidence-based management strategies.
Histologic Subtypes and Kidney Outcomes in Lupus Nephritis: Insights from a Diverse Cohort at a Quaternary Care Center
Bobart, Shane A. , Riaz, Maryam , Camacho, A. A., Daliri, Soudabeh, Javed, Mahnoor, Lowe, Jessica Elise, Lin, Yueh-Yun , Deva, Anshuj, Sanghvi, Aarjav Atik, Aslam, Nabeel , Adrogué, Horacio E. , Guevara, Myriam , Edwards, Angelina , Camacho, Alma A Aveytia, Deva, Anshuj, Sanghvi, Aarjav Atik, Hickson, LaTonya J.

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025j83c0b42 Get It

Clinical and Pathological Characteristics of Patients with Lupus Nephritis and Concomitant Thrombotic Microangiopathy
Bobart, Shane A. , Javed, Mahnoor, Camacho, A. A., Riaz, Maryam , Lowe, Jessica Elise, Aslam, Nabeel , Adrogué, Horacio E. , Edwards, Angelina , Guevara, Myriam , Camacho, Alma A Aveytia, Hickson, LaTonya J.

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025pqx5nr67 Get It

Clinical phenotypes and renal outcomes in PLA2R-associated membranous nephropathy: a multi-center cohort study with unsupervised cluster analysis
Miao, Jing , Zand, Jaleh , Vaughan, Lisa E. , Soler, María José , Quintana, Luís F. , Thongprayoon, Charat, Wooden, Benjamin , Bobart, Shane A. , Cheungpasitporn, Wisit, Zand, Ladan , Cheungpasitporn, Wisit , Quintana, Luis F , Bobart, Shane A , Fervenza, Fernando C , Cheungpasitporn, Wisit , Soler, Maria Jose , Miao, Jing , Encarnación, Montserrat M. Díaz , Bomback, Andrew S. , Thongprayoon, Charat , Fervenza, Fernando C.

Mayo Clinic

Nephrology Dialysis Transplantation | June 18, 2025 | Volume: 40 | Issue: 12 | Pages: 2309-2318

10.1093/ndt/gfaf107 | PMID 40577236 Get It

ABSTRACT Background Membranous nephropathy (MN) associated with phospholipase A2 receptor (PLA2R) antibodies is the most common cause of nephrotic syndrome in non-diabetic adult patients. This study investigated the relationship between clinical phenotypes and renal outcomes in this population, emphasizing the potential for phenotype-based treatment stratification. Methods We conducted a retrospective, multi-center cohort study of PLA2R-positive MN. Unsupervised cluster analysis grouped patients based on clinicopathological characteristics. Primary outcomes included complete or partial remission within 2 years of biopsy and end-stage kidney disease (ESKD) or death during follow-up. Results Among 178 patients, three distinct clusters emerged (n = 89, 70, and 19). Within 2 years of biopsy, 102 patients (57%) achieved complete or partial remission. Cluster 1, characterized by the mildest disease markers, including the lowest body mass index, serum anti-PLA2R titer, serum creatinine, proteinuria, and triglycerides, had the highest remission rate of 72%, compared with 50% in cluster 2 and 54% in cluster 3. Cluster 2 had significantly lower remission compared to cluster 1 (HR 0.64, 95% CI 0.42–0.96, P = .03); results were similar in cluster 3, albeit not statistically significant (HR 0.50, 95% CI 0.23–1.09, P = .08). Elevated anti-PLA2R levels (&gt;100 U/ml) and proteinuria (&gt;8 g/24-hour) predicted reduced remission (HR 0.56, 95% CI 0.36–0.88, P = .01; HR 0.43, 95% CI 0.26–0.73, P = .002, respectively), while high high-density lipoprotein levels were protective (HR 1.01, 95% CI 1.00–1.02, P = .048). Overall, 21 patients (12%) developed ESKD or died. ESKD-free survival differed significantly across clusters (log-rank test P = .04). Conclusions Unsupervised clustering identified distinct clinical phenotypes in PLA2R-positive MN, each associated with different renal prognoses. Phenotype-based risk stratification could enhance treatment precision, improve patient outcomes, and potentially reduce treatment-related adverse effects.
Targeting the Optimal Antibody Strategy for a Noninvasive Diagnosis of Phospholipase A2 Receptor–Associated Membranous Nephropathy
Bobart, Shane A. , Fervenza, Fernando C. , Fervenza, Fernando C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 8, 2025 | Volume: 20 | Issue: 5 | Pages: 598-600

10.2215/cjn.0000000710 | PMID 40338635 Get It

Urine Proteomics of Primary vs. Secondary Focal Segmental Glomerulosclerosis: Is There a Potential Noninvasive Urine Biomarker?
Russo, Ilario , Bobart, Shane A. , Vargas-Brochero, Maria Jose, Chavez, Coraima Claudia Nava , Charlesworth, M. Cristine , Sethi, Sanjeev , Mekraksakit, Poemlarp , Vargas-Brochero, Maria J. , Krisanapan, Pajaree , Madden, Benjamin J. , Fervenza, Fernando C.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024672m26k3 Get It

Use of Urinary Proteins as Predictors of Response to Immunosuppressive Treatment in Membranous Nephropathy
Androga, Lagu A. , Viehman, Jason K., Bobart, Shane A. , Vaughan, Lisa E. , Zand, Ladan , Greene, Eddie L., Sethi, Sanjeev , Cattran, Daniel, Lieske, John C. , Fervenza, Fernando C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 484-484

10.1681/asn.20213210s1484b Get It

Noninvasive Diagnosis of Primary Membranous Nephropathy Using Anti-Phospholipase A2 Receptor (PLA2R) Antibodies: A Validation Study
Bobart, Shane A. , Gómez, Cristina Andrades, Sethi, Sanjeev , Giesen, Callen D., Tehranian, Shahrzad , Lieske, John C. , Vriese, An S. De , Fervenza, Fernando C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 590-590

10.1681/asn.20203110s1590a Get It

A Target Antigen-Based Approach to the Classification of Membranous Nephropathy
Bobart, Shane A. , Sethi, Sanjeev , Alexander, Mariam P., Nasr, Samih H. , Vrana, Julie A. , Said, Samar M. , Giesen, Callen D., Tehranian, Shahrzad , Lieske, John C. , Fervenza, Fernando C. , Vriese, An S. De

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 589-590

10.1681/asn.20203110s1589d Get It